GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncimmune Holdings PLC (LSE:ONC) » Definitions » LT-Debt-to-Total-Asset

Oncimmune Holdings (LSE:ONC) LT-Debt-to-Total-Asset : 0.67 (As of Aug. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Oncimmune Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Oncimmune Holdings's long-term debt to total assests ratio for the quarter that ended in Aug. 2024 was 0.67.

Oncimmune Holdings's long-term debt to total assets ratio increased from Aug. 2023 (0.59) to Aug. 2024 (0.67). It may suggest that Oncimmune Holdings is progressively becoming more dependent on debt to grow their business.


Oncimmune Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Oncimmune Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncimmune Holdings LT-Debt-to-Total-Asset Chart

Oncimmune Holdings Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 Aug23 Aug24
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.67 0.36 0.16 0.59 0.67

Oncimmune Holdings Semi-Annual Data
Nov14 May15 Nov15 May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Feb23 Aug23 Feb24 Aug24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.56 0.59 0.72 0.67

Oncimmune Holdings LT-Debt-to-Total-Asset Calculation

Oncimmune Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Aug. 2024 is calculated as

LT Debt to Total Assets (A: Aug. 2024 )=Long-Term Debt & Capital Lease Obligation (A: Aug. 2024 )/Total Assets (A: Aug. 2024 )
=3.293/4.902
=0.67

Oncimmune Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Aug. 2024 is calculated as

LT Debt to Total Assets (Q: Aug. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Aug. 2024 )/Total Assets (Q: Aug. 2024 )
=3.293/4.902
=0.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncimmune Holdings  (LSE:ONC) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Oncimmune Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Oncimmune Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncimmune Holdings Business Description

Traded in Other Exchanges
N/A
Address
1 Park Row, MediCity - D6 Building, Leeds, GBR, LS1 5AB
Oncimmune Holdings PLC is engaged in diagnosing cancer. It is involved in the development, manufacturing, and commercialization of personalized immunodiagnostics for the screening, detection, and care of cancer. The company's operating segment is ImmunoINSIGHTS.